Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5288775
Max Phase: Preclinical
Molecular Formula: C49H91N16O15+
Molecular Weight: 1144.36
Associated Items:
ID: ALA5288775
Max Phase: Preclinical
Molecular Formula: C49H91N16O15+
Molecular Weight: 1144.36
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCC[N+](C)(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)O)[C@@H](C)O
Standard InChI: InChI=1S/C49H90N16O15/c1-25(56-41(72)31(16-10-12-20-50)61-46(77)36(51)29(5)67)38(69)55-26(2)39(70)59-33(18-14-21-54-49(52)53)42(73)60-32(17-11-13-23-65(7,8)9)43(74)62-34(24-66)44(75)58-28(4)47(78)64-22-15-19-35(64)45(76)57-27(3)40(71)63-37(30(6)68)48(79)80/h25-37,66-68H,10-24,50-51H2,1-9H3,(H13-,52,53,54,55,56,57,58,59,60,61,62,63,69,70,71,72,73,74,75,76,77,79,80)/p+1/t25-,26-,27-,28-,29+,30+,31-,32-,33-,34-,35-,36-,37-/m0/s1
Standard InChI Key: XHKDRHQMSGQEMN-XNPDXUETSA-O
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1144.36 | Molecular Weight (Monoisotopic): 1143.6844 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Tomassi S, Romanelli A, Zwergel C, Valente S, Mai A.. (2021) Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders., 64 (16.0): [PMID:34351144] [10.1021/acs.jmedchem.1c00226] |
Source(1):